Last reviewed · How we verify
Levonorgestrel-releasing intrauterine system
At a glance
| Generic name | Levonorgestrel-releasing intrauterine system |
|---|---|
| Also known as | Mirena |
| Sponsor | University of North Carolina, Chapel Hill |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia (PHASE2, PHASE3)
- Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer
- Oral Contraceptive Pills Versus Levonorgestrel-Releasing Intrauterine System for Niche-Related Abnormal Uterine Bleeding (NA)
- Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer (PHASE2)
- The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies (PHASE1)
- Subdermal Implant-bioabsorbable Gestrinone Pellet for Endometriosis Pelvic Pain Treatment (PHASE2)
- Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer (PHASE2)
- Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: